Traders Buy Large Volume of Compass Pathways Call Options (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of unusually large options trading activity on Monday. Investors purchased 24,075 call options on the company. This is an increase of approximately 335% compared to the typical daily volume of 5,530 call options.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. grew its position in shares of Compass Pathways by 169.0% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock valued at $2,931,000 after purchasing an additional 266,908 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Compass Pathways in the third quarter worth about $7,890,000. Propel Bio Management LLC purchased a new stake in shares of Compass Pathways in the third quarter worth about $2,922,000. Blue Owl Capital Holdings LP lifted its position in shares of Compass Pathways by 163.1% in the third quarter. Blue Owl Capital Holdings LP now owns 604,914 shares of the company’s stock worth $3,466,000 after buying an additional 375,000 shares in the last quarter. Finally, ARK Investment Management LLC boosted its stake in Compass Pathways by 28.6% during the third quarter. ARK Investment Management LLC now owns 2,121,118 shares of the company’s stock valued at $12,154,000 after buying an additional 471,897 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Stock Up 1.6%

CMPS traded up $0.20 during trading on Monday, hitting $12.72. 2,312,301 shares of the company’s stock traded hands, compared to its average volume of 3,608,655. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -4.04 and a beta of 2.50. The company’s 50 day simple moving average is $10.22 and its two-hundred day simple moving average is $7.86. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $14.76. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Analysts predict that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen raised Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. UBS Group set a $18.00 price objective on shares of Compass Pathways in a report on Thursday, May 7th. Jefferies Financial Group upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Tuesday, May 5th. Maxim Group raised their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Morgan Stanley boosted their price target on shares of Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.